Beta Bionics, Inc. (NASDAQ: BBNX) is a Healthcare company (Medical - Devices) with a market capitalization of $662M. The Maz Rating grades it against the other companies in its sector.
Beta Bionics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $14.72, Beta Bionics, Inc. trades at 5.2x sales and 1.7x book value. Over the last twelve months it generated about $127M of revenue and a net loss of $84M. It runs a gross margin of 58.6%, an operating margin of -72.7% and a net margin of -65.3%. It shows return on equity of -27.3%, return on invested capital of -22.5% and a free cash flow yield of -9.9%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 8.92. Over the past 52 weeks the share price ranged from $8.80 to $32.71, with a beta of 3.43.
Beta Bionics, Inc. does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 6 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Beta Bionics, Inc. (BBNX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 44.7% / 30% · Interest income / Revenue 6.36% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 28.7% / 33% · Receivables / Mkt Cap (36m) 2.81% / 49% · Interest income / Revenue 6.36% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 28.7% / 33.33% · Receivables / Mkt Cap (24m) 2.81% / 33.33% · Interest income / Revenue 6.36% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 61.3% / 33.33% · Receivables / Avg Assets (4Q) 5.93% / 33.33% · Interest income / Revenue 6.36% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 54.1% / 33.33% · (Cash+Recv) / Total Assets 59.4% / 33.33% · Interest income / Revenue 6.36% / 5% | Fail |
No. As of September 2026, Beta Bionics, Inc. (BBNX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Beta Bionics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 6.36% of each dividend: Beta Bionics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.